Pfizer PFE Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenues: by Product | ||||||
| Abrysvo | $180M-62.5% | $480M+72.0% | $279M+95.1% | $143M+9.2% | $131M-33.8% | |
| Adcetris | $190M-13.6% | $220M+2.3% | $215M-15.7% | $255M+17.0% | $218M-23.5% | |
| All Other Hospital and Biosimilars | $953M— | —— | —— | —— | $901M— | |
| All other Oncology | $376M+24.1% | $303M+11.4% | $272M-28.4% | $380M+0.8% | $377M+32.3% | |
| All other Primary Care | $654M-17.1% | $789M+9.4% | $721M-2.0% | $736M+20.9% | $609M-22.6% | |
| All other Specialty Care | $579M+21.6% | $476M+17.0% | $407M+4.4% | $390M-19.8% | $486M+41.3% | |
| Bosulif | $129M-19.9% | $161M+7.3% | $150M+0.7% | $149M-1.3% | $151M-11.7% | |
| Braftovi/Mektovi | $174M-11.7% | $197M-2.5% | $202M+11.0% | $182M+33.8% | $136M-20.0% | |
| Cibinqo | $76M-2.6% | $78M-1.3% | $79M+14.5% | $69M+19.0% | $58M-7.9% | |
| Comirnaty | $232M-89.8% | $2.27B+97.2% | $1.15B+202% | $381M-32.6% | $565M-83.3% | |
| Eliquis | $2.17B+7.2% | $2.02B+0.2% | $2.02B+0.6% | $2B+4.2% | $1.92B+5.0% | |
| Elrexfio | $80M+8.1% | $74M-12.9% | $85M0.0% | $85M+41.7% | $60M+5.3% | |
| Enbrel (Outside the U.S. and Canada) | $138M-22.9% | $179M+16.2% | $154M0.0% | $154M+10.0% | $140M-23.5% | |
| FSME-IMMUN/TicoVac | $81M+72.3% | $47M-53.0% | $100M-8.3% | $109M+73.0% | $63M+85.3% | |
| Genotropin | $93M-20.5% | $117M-8.6% | $128M+20.8% | $106M+11.6% | $95M-15.2% | |
| Ibrance | $1.01B-3.0% | $1.04B-1.7% | $1.06B+0.8% | $1.05B+7.4% | $977M-10.8% | |
| Inflectra | $182M— | —— | $173M+24.5% | $139M-9.2% | $153M— | |
| Inlyta | $214M-8.9% | $235M+4.0% | $226M-7.0% | $243M+11.0% | $219M-9.5% | |
| Lorbrena | $305M+8.2% | $282M+5.2% | $268M+6.8% | $251M+13.1% | $222M+15.0% | |
| Nurtec ODT/Vydura | $353M-12.8% | $405M-1.7% | $412M+14.8% | $359M+44.8% | $248M-36.9% | |
| Octagam | $122M+1.7% | $120M+6.2% | $113M+16.5% | $97M+10.2% | $88M-19.3% | |
| Oncology Biosimilars | $409M+10.8% | $369M+17.1% | $315M-10.8% | $353M+33.7% | $264M+26.3% | |
| Orgovyx | $109M-19.9% | $136M+21.4% | $112M+15.5% | $97M+27.6% | $76M+16.9% | |
| Padcev | $591M+16.3% | $508M+9.5% | $464M-14.4% | $542M+27.2% | $426M-4.1% | |
| Paxlovid | $186M— | —— | $1.23B+187% | $427M-13.0% | $491M— | |
| Pfizer CentreOne | $289M-29.3% | $409M+18.9% | $344M+4.9% | $328M+20.1% | $273M-16.3% | |
| Prevnar Family | $1.69B-1.1% | $1.71B-2.0% | $1.74B+26.0% | $1.38B-16.7% | $1.66B+6.5% | |
| Sulperazon (Outside the U.S. and Canada) | $199M+17.8% | $169M+9.7% | $154M-7.2% | $166M+1.2% | $164M-3.0% | |
| Talzenna | $50M+2.0% | $49M+4.3% | $47M+2.2% | $46M+15.0% | $40M+53.8% | |
| Tivdak | $33M+3.1% | $32M-13.5% | $37M-19.6% | $46M+39.4% | $33M-10.8% | |
| Tukysa | $122M+2.5% | $119M+8.2% | $110M-16.7% | $132M+29.4% | $102M-20.9% | |
| Vyndaqel family | $1.6B-5.1% | $1.69B+6.1% | $1.59B-1.5% | $1.62B+8.7% | $1.49B-3.8% | |
| Xeljanz | $180M-44.4% | $324M+3.5% | $313M-2.8% | $322M+152% | $128M-63.4% | |
| Xtandi | $444M-25.0% | $592M+2.4% | $578M+2.1% | $566M+23.6% | $458M-18.9% | |
| Zavicefta (Outside the U.S. and Canada) | $150M-17.1% | $181M+14.6% | $158M-3.1% | $163M+20.7% | $135M-15.1% | |
| Zithromax | $112M-0.9% | $113M+54.8% | $73M+30.4% | $56M-64.6% | $158M+28.5% | |
| Indefinite-lived intangible assets, period increase (decrease) by Product | ||||||
| Tukysa | -$580M— | —— | —— | —— | —— | |
| Revenues: by Geography | ||||||
| International Developed Markets | $3.43B-42.1% | $5.92B+60.2% | $3.7B+8.9% | $3.39B+6.8% | $3.18B-49.4% | |
| International Emerging Markets | $2.29B-8.9% | $2.52B+11.0% | $2.27B-4.2% | $2.37B+9.4% | $2.16B-4.2% | |
| U.S. | $8.73B-4.3% | $9.12B-14.7% | $10.69B+20.2% | $8.89B+6.2% | $8.37B-9.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Pfizer break its business down?
- Pfizer (PFE) reports revenues: by product across 36 parts — Abrysvo, Adcetris, All Other Hospital and Biosimilars, All other Oncology and All other Primary Care. Each is extracted from the segment footnotes and tracked over time.
- Where does Pfizer's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Pfizer's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
